Septerna initiated with a Buy at JonesResearch

JonesResearch initiated coverage of Septerna (SEPN) with a Buy rating and $43 price target Septerna is a clinical stage biotech focused on identifying novel ways to target G protein-coupled receptors with small molecules, the analyst tells investors in a research note. The firm says the company’s lead endocrine program is SEP-479 for hypoparathyroidism with a Phase 1 initiating in the first half of 2026. Jones forecasts $2.5B in unadjusted U.S. peak sales in 2035.